TransCode licenses cancer immunotherapy platform in stock deal Mar 3, 2026 08:03AM
TransCode publishes preclinical data on glioblastoma treatment Jan 6, 2026 08:01AM
TransCode Therapeutics (RNAZ) files $150M mixed shelf Dec 12, 2025 04:19PM
TransCode Therapeutics appoints Dr. Michel Janicot as senior development officer Nov 17, 2025 08:01AM
TransCode Therapeutics acquires Polynoma for $25 million from CK Life Sciences Oct 8, 2025 08:04AM


May 28, 2025 08:01AM TransCode Therapeutics (RNAZ) Appoints Dr. Phillip D. Zamore to Science Advisory Board
May 2, 2025 04:11PM TransCode Therapeutics (RNAZ) Announces 1:28 Reverse Share Split
May 1, 2025 09:01AM TransCode Therapeutics (RNAZ) Reports Further Progress on Phase 1a Clinical Trial with No Dose Limiting Toxicities Reported in Patients with Metastatic Cancer
Mar 27, 2025 04:39PM TransCode Therapeutics (RNAZ) announces phase one initial dosing of TTX-MC138
Feb 6, 2025 08:09AM TransCode Therapeutics (RNAZ) Announces Completion of Cohort 3 Initial Dosing with Lead Candidate in Phase 1 Clinical Trial
Dec 19, 2024 06:40AM ransCode Therapeutics Inc (RNAZ) PT Raised to $20 at H.C. Wainwright
Dec 18, 2024 08:00AM TransCode Therapeutics (RNAZ) Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary Results from First Cohort in Phase 1 TTX-MC138 Trial
Nov 27, 2024 07:00AM TransCode Therapeutics (RNAZ) Prices 21.22M Share Offering at $0.377/sh
Nov 25, 2024 07:02AM TransCode Therapeutics (RNAZ) Announces 1:33 Reverse Share Split
Nov 12, 2024 07:04AM TransCode Therapeutics (RNAZ) Issues Letter to Shareholders
Nov 5, 2024 07:01AM TransCode Therapeutics (RNAZ) Regains Nasdaq Extension to Regain Compliance
Oct 23, 2024 07:01AM TransCode Therapeutics (RNAZ) Announces Safety Review Committee Approval of Second Cohort Opening in Phase 1 TTX-MC138 Clinical Trial Following Favorable Review of Cohort 1 Safety Data
Sep 17, 2024 07:01AM TransCode Therapeutics (RNAZ) Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate
Sep 10, 2024 07:02AM TransCode Therapeutics (RNAZ) Announces Publication of Study with Lead Therapeutic Candidate Revealing Mechanisms Behind Candidate’s Preclinical Efficacy Against Metastatic Cancer
Sep 6, 2024 06:58AM H.C. Wainwright Reiterates Buy Rating on ransCode Therapeutics Inc (RNAZ)
Sep 5, 2024 07:03AM TransCode Therapeutics (RNAZ) Receives $2M NIH Grant to Support Clinical Evaluation of TTX-MC138
Jul 22, 2024 04:07PM TransCode Therapeutics (RNAZ) Announces Proposed Share Offering
Jun 10, 2024 06:03AM Nasdaq Determines That TransCode Therapeutics (RNAZ) Has Regained Compliance with Continued Listing Requirements